Jim Cramer spoke with the CEO of GW Pharmaceuticals following breakthrough results for its drug Epidiolex. » Read More
By: Kelly Evans
Rep. Elijah Cummings (D-Maryland) reacts to the new report saying pre-tax profits on Mylan's EpiPen were 60 percent higher than CEO Heather Bresch told Congress last week. CNBC's Meg Tirrell reports. » Read More
A serious warning on Pfizer's quit smoking drug should be removed, panelists to the U.S. Food and Drug Administration recommended on Wednesday.
Shares of Allergan jumped after announcing it would buy drug developer Vitae Pharmaceuticals for about $639 million.
Sarepta Therapeutics surge Wednesday after reports a critic of its muscular dystrophy drug left the U.S. Food and Drug Administration.
Chemicals group poised to announce deal to buy U.S. seeds company Monsanto for more than $66 billion, people familiar with the matter told Reuters.
Guggenheim Securities managing director Eric Wasserstrom weighs in on the big changes and next steps for Wells Fargo.
The "Fast Money" traders debated whether it's time to pile into the biotech sector after the sector gained 3 percent on Monday.
CNBC's Meg Tirrell takes a look at what may be ahead on the horizon for healthcare, with the likes of Obamacare and drug prices in the midst of the presidential campaign.
Rich Ross, Evercore ISI, and Max Wolff, Manhattan Venture Partners, discuss the moves in the biotech sector with Brian Sullivan.
The biotechnology sector made sizeable gains on Monday amid acquisition news.
Taro and two of its senior officers received subpoenas last week in connection with a federal antitrust investigation into generic drug pricing.
Sanofi and Alphabet's life sciences firm Verily will invest about $500 million in a diabetes joint venture combining devices with services.
With allergies on the rise, theories examining why are being explored. One is linked to our obsession with fighting germs.
Mylan expects the generic version of EpiPens, to eventually account for 85% of sales of its auto-injection, anti-allergy devices.
CNBC's Meg Tirrell reports the latest on the response from EpiPen maker Mylan to Sen. Chuck Grassley's inquiries over the controversial price hike for the drug.
"Fast Money Halftime Report" trader Jon Najarian discusses unusual activity in biotech stock Novavax.
"The market has been pricing in a closer election all summer," Strategas's head of policy research tells CNBC.
Get the best of CNBC in your inbox